{"id":50039,"date":"2025-12-05T23:42:11","date_gmt":"2025-12-05T15:42:11","guid":{"rendered":"https:\/\/flcube.com\/?p=50039"},"modified":"2025-12-05T23:42:12","modified_gmt":"2025-12-05T15:42:12","slug":"sanofi-completes-vicebio-1-6b-acquisition-adds-rsv-vaccine-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50039","title":{"rendered":"Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform"},"content":{"rendered":"\n<p><strong>Sanofi<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>) announced the completion of its <strong>$1.6\u202fbillion acquisition<\/strong> of <strong>Vicebio<\/strong>, first announced in July\u202f2025. The deal adds an early\u2011stage combination vaccine candidate for <strong>respiratory syncytial virus (RSV)<\/strong> and human metapneumovirus (HMPV), along with Vicebio\u2019s proprietary <strong>\u2018Molecular Clamp\u2019 technology<\/strong>, expanding Sanofi\u2019s respiratory vaccine pipeline with a non\u2011mRNA option.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-acquisition-summary-amp-financial-terms\">Acquisition Summary &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Sanofi (NASDAQ: SNY)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Vicebio<\/td><\/tr><tr><td><strong>Deal Value<\/strong><\/td><td>USD\u202f1.6\u202fbillion<\/td><\/tr><tr><td><strong>Announcement<\/strong><\/td><td>July\u202f2025<\/td><\/tr><tr><td><strong>Closing<\/strong><\/td><td>04\u202fDec\u202f2025<\/td><\/tr><tr><td><strong>Technology Acquired<\/strong><\/td><td>Molecular Clamp vaccine platform<\/td><\/tr><tr><td><strong>Pipeline Asset<\/strong><\/td><td>Early\u2011stage RSV\/HMPV combination vaccine candidate<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-amp-pipeline-integration\">Technology Platform &amp; Pipeline Integration<\/h2>\n\n\n\n<p><strong>Vicebio\u2019s Molecular Clamp Technology:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Stabilizes viral fusion proteins in their pre\u2011fusion conformation<\/li>\n\n\n\n<li>Enhances immunogenicity and cross\u2011protection against respiratory viruses<\/li>\n\n\n\n<li>Complements Sanofi\u2019s existing mRNA and protein\u2011based vaccine platforms<\/li>\n<\/ul>\n\n\n\n<p><strong>RSV\/HMPV Vaccine Candidate:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication<\/strong>: Combination vaccine for RSV and human metapneumovirus<\/li>\n\n\n\n<li><strong>Stage<\/strong>: Early\u2011stage development (pre\u2011clinical\/Phase\u202f1 ready)<\/li>\n\n\n\n<li><strong>Strategic Value<\/strong>: Addresses two leading causes of respiratory infections in infants and elderly<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-market-position\">Strategic Rationale &amp; Market Position<\/h2>\n\n\n\n<p><strong>Non\u2011mRNA Differentiation:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Expands Sanofi\u2019s respiratory portfolio beyond mRNA vaccines<\/li>\n\n\n\n<li>Offers physicians and patients alternative technology options<\/li>\n\n\n\n<li>Reduces reliance on single platform for respiratory disease prevention<\/li>\n<\/ul>\n\n\n\n<p><strong>Pipeline Synergy:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Leverages Sanofi\u2019s global vaccine manufacturing and commercial infrastructure<\/li>\n\n\n\n<li>Integrates with existing RSV program (including infant and maternal immunization strategies)<\/li>\n\n\n\n<li>Strengthens position in pediatric and adult respiratory vaccine markets<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market Segment<\/th><th>Annual Burden<\/th><th>Current Leaders<\/th><th>Sanofi Position<\/th><\/tr><\/thead><tbody><tr><td><strong>RSV (Infants)<\/strong><\/td><td>3.6M hospitalizations globally<\/td><td>GSK (Arexvy), Pfizer (Abrysvo)<\/td><td>Enhanced portfolio with non\u2011mRNA option<\/td><\/tr><tr><td><strong>RSV (Older Adults)<\/strong><\/td><td>177K hospitalizations (US)<\/td><td>GSK, Pfizer<\/td><td>Market leader potential via diversified platforms<\/td><\/tr><tr><td><strong>HMPV<\/strong><\/td><td>10\u201116% of pediatric respiratory infections<\/td><td>No approved vaccines<\/td><td>First\u2011mover advantage in combination approach<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Commercial Opportunity:<\/strong> RSV vaccine market projected to exceed <strong>$10\u202fbillion<\/strong> globally by 2030; combination HMPV\/RSV vaccine could capture premium pricing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-integration-outlook\">Financial &amp; Integration Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>R&amp;D Investment<\/strong>: $1.6B acquisition price includes platform technology and candidate pipeline<\/li>\n\n\n\n<li><strong>Cost Synergies<\/strong>: Integration into Sanofi\u2019s vaccine R&amp;D infrastructure expected to reduce development costs by 20\u201130%<\/li>\n\n\n\n<li><strong>Revenue Timeline<\/strong>: Phase\u202f1 initiation H1\u202f2026; potential launch 2029\u20112030 if successful<\/li>\n\n\n\n<li><strong>Pipeline Expansion<\/strong>: Molecular Clamp platform applicable to other viral targets (influenza, coronaviruses)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the integration of Vicebio\u2019s technology, development timelines for the RSV\/HMPV vaccine candidate, and projected market opportunities. Actual results may differ due to clinical, regulatory, competitive, and integration risks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi (NASDAQ: SNY) announced the completion of its $1.6\u202fbillion acquisition of Vicebio, first announced in&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50040,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[867,147,12,4233],"class_list":["post-50039","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-nasdaq-sny","tag-sanofi","tag-vaccine","tag-vicebio"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi (NASDAQ: SNY) announced the completion of its $1.6\u202fbillion acquisition of Vicebio, first announced in July\u202f2025. The deal adds an early\u2011stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), along with Vicebio\u2019s proprietary \u2018Molecular Clamp\u2019 technology, expanding Sanofi\u2019s respiratory vaccine pipeline with a non\u2011mRNA option.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50039\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform\" \/>\n<meta property=\"og:description\" content=\"Sanofi (NASDAQ: SNY) announced the completion of its $1.6\u202fbillion acquisition of Vicebio, first announced in July\u202f2025. The deal adds an early\u2011stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), along with Vicebio\u2019s proprietary \u2018Molecular Clamp\u2019 technology, expanding Sanofi\u2019s respiratory vaccine pipeline with a non\u2011mRNA option.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50039\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-05T15:42:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-05T15:42:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0504.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50039#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50039\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform\",\"datePublished\":\"2025-12-05T15:42:11+00:00\",\"dateModified\":\"2025-12-05T15:42:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50039\"},\"wordCount\":405,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50039#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0504.webp\",\"keywords\":[\"NASDAQ: SNY\",\"Sanofi\",\"Vaccine\",\"Vicebio\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50039#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50039\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50039\",\"name\":\"Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50039#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50039#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0504.webp\",\"datePublished\":\"2025-12-05T15:42:11+00:00\",\"dateModified\":\"2025-12-05T15:42:12+00:00\",\"description\":\"Sanofi (NASDAQ: SNY) announced the completion of its $1.6\u202fbillion acquisition of Vicebio, first announced in July\u202f2025. The deal adds an early\u2011stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), along with Vicebio\u2019s proprietary \u2018Molecular Clamp\u2019 technology, expanding Sanofi\u2019s respiratory vaccine pipeline with a non\u2011mRNA option.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50039#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50039\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50039#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0504.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0504.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50039#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform - Insight, China&#039;s Pharmaceutical Industry","description":"Sanofi (NASDAQ: SNY) announced the completion of its $1.6\u202fbillion acquisition of Vicebio, first announced in July\u202f2025. The deal adds an early\u2011stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), along with Vicebio\u2019s proprietary \u2018Molecular Clamp\u2019 technology, expanding Sanofi\u2019s respiratory vaccine pipeline with a non\u2011mRNA option.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50039","og_locale":"en_US","og_type":"article","og_title":"Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform","og_description":"Sanofi (NASDAQ: SNY) announced the completion of its $1.6\u202fbillion acquisition of Vicebio, first announced in July\u202f2025. The deal adds an early\u2011stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), along with Vicebio\u2019s proprietary \u2018Molecular Clamp\u2019 technology, expanding Sanofi\u2019s respiratory vaccine pipeline with a non\u2011mRNA option.","og_url":"https:\/\/flcube.com\/?p=50039","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-05T15:42:11+00:00","article_modified_time":"2025-12-05T15:42:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0504.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50039#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50039"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform","datePublished":"2025-12-05T15:42:11+00:00","dateModified":"2025-12-05T15:42:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50039"},"wordCount":405,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50039#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0504.webp","keywords":["NASDAQ: SNY","Sanofi","Vaccine","Vicebio"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50039#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50039","url":"https:\/\/flcube.com\/?p=50039","name":"Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50039#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50039#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0504.webp","datePublished":"2025-12-05T15:42:11+00:00","dateModified":"2025-12-05T15:42:12+00:00","description":"Sanofi (NASDAQ: SNY) announced the completion of its $1.6\u202fbillion acquisition of Vicebio, first announced in July\u202f2025. The deal adds an early\u2011stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), along with Vicebio\u2019s proprietary \u2018Molecular Clamp\u2019 technology, expanding Sanofi\u2019s respiratory vaccine pipeline with a non\u2011mRNA option.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50039#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50039"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50039#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0504.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0504.webp","width":1080,"height":608,"caption":"Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50039#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0504.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50039"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50039\/revisions"}],"predecessor-version":[{"id":50041,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50039\/revisions\/50041"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50040"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}